|
1
|
Krystof V and Uldrijan S: Cyclin-dependent
kinase inhibitors as anticancer drugs. Curr Drug Targets.
11:291–302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meijer L, Borgne A, Mulner O, Chong JP,
Blow JJ, Inagaki N, Inagaki M, Delcros JG and Moulinoux JP:
Biochemical and cellular effects of roscovitine, a potent and
selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and
cdk5. Eur J Biochem. 243:527–536. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Payton M, Chung G, Yakowec P, Wong A,
Powers D, Xiong L, Zhang N, Leal J, Bush TL, Santora V, et al:
Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer
Res. 66:4299–4308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dey A, Wong ET, Cheok CF, Tergaonkar V and
Lane DP: R-Roscovitine simultaneously targets both the p53 and
NF-kappaB pathways and causes potentiation of apoptosis:
Implications in cancer therapy. Cell Death Differ. 15:263–273.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rossi AG, Sawatzky DA, Walker A, Ward C,
Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR,
Duffin R, et al: Cyclin-dependent kinase inhibitors enhance the
resolution of inflammation by promoting inflammatory cell
apoptosis. Nat Med. 12:1056–1064. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leitch AE, Riley NA, Sheldrake TA, Festa
M, Fox S, Duffin R, Haslett C and Rossi AG: The cyclin-dependent
kinase inhibitor R-roscovitine down-regulates Mcl-1 to override
pro-inflammatory signalling and drive neutrophil apoptosis. Eur J
Immunol. 40:1127–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SM, Yun MR, Hong YK, Solca F, Kim JH,
Kim HJ and Cho BC: Glycolysis inhibition sensitizes non-small cell
lung cancer with T790M mutation to irreversible EGFR inhibitors via
translational suppression of Mcl-1 by AMPK activation. Mol Cancer
Ther. 12:2145–2156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yue W, Zheng X, Lin Y, Yang CS, Xu Q,
Carpizo D, Huang H, DiPaola RS and Tan XL: Metformin combined with
aspirin significantly inhibits pancreatic cancer cell growth in
vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and
Bcl-2. Oncotarget. 6:21208–21224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang ST, Huang SW, Kao JK, Liang SM, Chen
YJ, Chen YY, Wu CY and Shieh JJ: Imiquimod-induced AMPK activation
causes translation attenuation and apoptosis but not autophagy. J
Dermatol Sci. 78:108–116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nunes AK, Rapôso C, Rocha SW, Barbosa KP,
Luna RL, da Cruz-Höfling MA and Peixoto CA: Involvement of AMPK,
IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in
a demyelination model. Brain Res. 1627:119–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liong S and Lappas M: Activation of AMPK
improves inflammation and insulin resistance in adipose tissue and
skeletal muscle from pregnant women. J Physiol Biochem. 71:703–717.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hoogendijk AJ, Diks SH, van der Poll T,
Peppelenbosch MP and Wieland CW: Kinase activity profiling of
pneumococcal pneumonia. PLoS One. 6:e185192011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoogendijk AJ, Pinhancos SS, van der Poll
T and Wieland CW: AMP-activated protein kinase activation by
5-aminoimidazole-4-carbox-amide-1-β-D-ribofuranoside (AICAR)
reduces lipoteichoic acid-induced lung inflammation. J Biol Chem.
288:7047–7052. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong CY, Park JH, Ahn RS, Im SY, Choi HS,
Soh J, Mellon SH and Lee K: Molecular mechanism of suppression of
testicular steroidogenesis by proinflammatory cytokine tumor
necrosis factor alpha. Mol Cell Biol. 24:2593–2604. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dobashi M, Fujisawa M, Yamazaki T, Okuda
Y, Kanzaki M, Tatsumi N, Tsuji T, Okada H and Kamidono S:
Inhibition of steroidogenesis in Leydig cells by exogenous nitric
oxide occurs independently of steroidogenic acute regulatory
protein (star) mRNA. Arch Androl. 47:203–209. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liew SH, Meachem SJ and Hedger MP: A
stereological analysis of the response of spermatogenesis to an
acute inflammatory episode in adult rats. J Androl. 28:176–185.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tiancheng X and Yunfei X: Research
progress in separation and culture of mice leydig cells. J Clin
Pathol Res. 35:569–572. 2015.
|
|
19
|
Wu L, Xu B, Fan W, Zhu X, Wang G and Zhang
A: Adiponectin protects Leydig cells against proinflammatory
cytokines by suppressing the nuclear factor-κB signaling Pathway.
FEBS J. 280:3920–3927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shchelochkov AM, Nefedova IF, Chernova SN
and Vartanova OV: The regional indicators of male fertility in the
Samara oblast and causative factors of their alterations. Klin Lab
Diagn. 25–29. 2012.(In Russian). PubMed/NCBI
|
|
22
|
Carlsen E, Andersson AM, Petersen JH and
Skakkebaek NE: History of febrile illness and variation in semen
quality. Hum Reprod. 18:2089–2092. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qureshi ST, Larivière L, Leveque G,
Clermont S, Moore KJ, Gros P and Malo D: Endotoxin-tolerant mice
have mutations in Toll-like receptor 4 (Tlr4). J Exp Med.
189:615–625. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Parvinen M, Söder O, Mali P, Fröysa B and
Ritzén M: In vitro stimulation of stage-specific deoxyribonucleic
acid synthesis in rat seminiferous tubule segments by interleukin-1
alpha. Endocrinology. 129:1614–1620. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meijer L and Raymond E: Roscovitine and
other purines as kinase inhibitors. From starfish oocytes to
clinical trials. Acc Chem Res. 36:417–425. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cicenas J, Kalyan K, Sorokinas A,
Stankunas E, Levy J, Meskinyte I, Stankevicius V, Kaupinis A and
Valius M: Roscovitine in cancer and other diseases. Ann Transl Med.
3:1352015.PubMed/NCBI
|
|
27
|
Kolodziej M, Goetz C, Di Fazio P,
Montalbano R, Ocker M, Strik H and Quint K: Roscovitine has
anti-proliferative and pro-apoptotic effects on glioblastoma cell
lines: A pilot study. Oncol Rep. 34:1549–1556. 2015.PubMed/NCBI
|
|
28
|
Arisan ED, Akkoç Y, Akyüz KG, Kerman EM,
Obakan P, Çoker-Gürkan A and Palavan Ünsal N: Polyamines modulate
the roscovitine-induced cell death switch decision autophagy vs.
apoptosis in MCF-7 and MDA-MB-231 breast cancer cells. Mol Med Rep.
11:4532–4540. 2015.PubMed/NCBI
|
|
29
|
El-Alfy M, Luu-The V, Huang XF, Berger L,
Labrie F and Pelletier G: Localization if type 5
17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid
dehydrogenase, and androgen receptor in the human prostate by in
situ hybridization and immunocytochemistry. Endocrinology.
140:1481–1491. 1999. View Article : Google Scholar
|
|
30
|
Gingras S, Moriggl R, Groner B and Simard
J: Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4
isomerase type 1 gene transcription in human breast cancer cell
lines and in normal mammary epithelial cells by interleukin-4 and
interleukin-13. Mol Endocrinol. 13:66–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gingras S and Simard J: Induction of
3beta-hydroxysteroid dehydrogenase/isomerase type 1expression by
interleukin-4 in human normal prostate epithelial cells,
immortalized keratinocytes, colon, and cervix cancer cell lines.
Endocrinology. 140:4573–4584. 1999. View Article : Google Scholar
|
|
32
|
Xue LY, Li J, Wang GX, Xiu HM and Sun HC:
The functional change of the rats testis in the condition of
undifferential orchitis induced by lipopolysaccharide. Reproduction
& Contraception. 26:77–80. 2006.
|
|
33
|
Chen L, Lai YS and Ji H: Effect of
COX/5-LOX dual inhibitor ZLJ-6 on the expression of LPS-induced
inflammation factors in macrophage cells. Journal of China
Pharmaceutical University. 43:70–74. 2012.
|
|
34
|
Yang KY, Gu JL, Yin DM and Shen Q: Effect
of Curcumin on iNOS Expression in LPS-activated Microglia Cells and
Ant-i oxidation. Chinese Journal of Biochemistry and Molecular
Biology. 23:938–945. 2007.
|
|
35
|
Ewart MA, Kohlhaas CF and Salt IP:
Inhibition of tumor necrosis factor alpha-stimulated monocyte
adhesion to human aortic endothelial cells by AMP-activated protein
kinase. Arterioscler Thromb Vasc Biol. 28:2255–2257. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giri S, Nath N, Smith B, Viollet B, Singh
AK and Singh I:
5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits
proinflammatory response in glial cells: A possible role of
AMP-activated protein kinase. J Neurosci. 24:479–487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yeung F, Hoberg JE, Ramsey CS, Keller MD,
Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent
transcription and cell survival by the SIRT1 deacetylase. EMBO J.
23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ak P and Levine AJ: P53 and NF-κB:
Different strategies for responding to stress lead to a functional
antagonism. FASEB J. 24:3643–3652. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Komarova EA, Krivokrysenko V, Wang K,
Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV,
Rokhlin OW, Kuprash DV, et al: p53 is a suppressor of inflammatory
response in mice. FASEB J. 19:1030–1032. 2005.PubMed/NCBI
|
|
40
|
Yu M, Zhang LY, Qiao PH and Chang B:
Testicular oxidative stress and downregulation of CYP17a1 induced
by di(n-butyl) phthalate inhibit synthesis of testosterone. Wei
Sheng Yan Jiu. 44:364–370. 2015.PubMed/NCBI
|
